Dapsone response in immune thrombocytopenic purpura is associated with dapsone dose and mediated through reduction in haemoglobin: A longitudinal data analysis of 58 adult and paediatric ITP patients demonstrates efficacy and safety

Documenti analoghi

• Facing the bleeding risk of caplacizumab in postpartum immune thrombotic thrombocytopenic purpura in constrained resource settings
  di: José Rojas‐Suarez, et al.
  Pubblicazione: (2025)
• Long‐term efficacy and safety of hetrombopag in paediatric patients with immune thrombocytopenia
  di: Jin‐Hua Wang, et al.
  Pubblicazione: (2026)
• Dapsone for paediatric chronic immune thrombocytopenia: Short report from a tertiary centre in South India
  di: Niteesh Bharadwaj, et al.
  Pubblicazione: (2024)
• Type I interferon as a pre‐lupus marker in anti‐nuclear antibody‐associated childhood immune thrombocytopenic purpura
  di: Jérôme Granel, et al.
  Pubblicazione: (2025)
• Successful management of refractory immune‐mediated thrombotic thrombocytopenic purpura during pregnancy and delivery using the anti‐VWF nanobody caplacizumab
  di: Roman R. Schimmer, et al.
  Pubblicazione: (2024)